GSK's two-drug HIV therapy shines in two big studies

LONDON (Reuters) - GlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to control the virus that causes AIDS.